39 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28621538	63	Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.	Novartis Pharma
28157311	11	Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.	Novartis Institutes For Biomedical Research
27994744	16	Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.	University of Michigan
24900799	3	Inhibitors of factor d may provide a treatment for age-related macular degeneration.	Therachem Research Medilab (India)
24900375	4	Factor D Inhibitors for the Treatment of AMD: Patent Highlight.	TBA
32551603	185	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.	Novartis Institutes For Biomedical Research
32073845	74	Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases	Novartis Institutes For Biomedical Research
30995036	52	Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.	Novartis Institutes For Biomedical Research
30295487	18	Ligand-Based Fluorine NMR Screening: Principles and Applications in Drug Discovery Projects.	Lavis
28977749	75	Chemical Approaches to Modulating Complement-Mediated Diseases.	The University of Queensland
29795765	32	Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.	Novartis Pharma
17539825	74	1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2.	Chemdiv
19703027	5	In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation.	University of Jordan
	83	Thermodynamic and Nuclear Magnetic Resonance Study of the Interactions of alpha-and beta-Cyclodextrin with Model Substances: Phenethylamine, Ephedrines, and Related Substances	Nist
19645433	37	Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.	St. Jude Research Hospital
17585749	56	Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.	Amgen
7562908	46	Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.	University of Auckland
10508432	12	Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.	Uppsala University